Format

Send to

Choose Destination
Sultan Qaboos Univ Med J. 2018 May;18(2):e223-e227. doi: 10.18295/squmj.2018.18.02.018. Epub 2018 Sep 9.

Rituximab Treatment in Myasthaenia Gravis: Report of two paediatric cases.

Author information

1
Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.
2
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.

Abstract

Myasthaenia gravis (MG) is an auto-immune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.

KEYWORDS:

Case Report; Children; Cholinergic Receptors; Myasthenia Gravis; Oman; Rituximab

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center